Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive phase I/II study of crovalimab in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria
2023-506287-14-00Phase 2Completed
- Sponsor
- Roche
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, open-label trial of crovalimab in paroxysmal nocturnal hemoglobinuria (PNH) (6 arms), sponsored by Roche. Primary endpoints: Incidence of dose-limiting events, Incidence and severity of adverse events and 3 more. Started Apr 2017; status: completed.
02
Drugs
crovalimab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2023-506287-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506287-14-00.